Clinical Trials Directory

Trials / Completed

CompletedNCT00002676

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Alliance for Clinical Trials in Oncology · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells and may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and whole-brain radiation therapy in patients with primary central nervous system non-Hodgkin's lymphoma.

Detailed description

OBJECTIVES: I. Assess the response to CHOD (cyclophosphamide/doxorubicin/vincristine/ dexamethasone) and BVAM (carmustine/vincristine/cytarabine/methotrexate) plus whole-brain radiotherapy in patients with primary central nervous system non-Hodgkin's lymphoma (PCNSL). II. Assess the toxic effects associated with this treatment. III. Assess the survival of patients with PCNSL receiving this treatment. IV. Investigate the frequency of systemic involvement at follow-up. V. Identify factors that appear to be associated with outcome.

Conditions

Interventions

TypeNameDescription
DRUGcarmustine
DRUGcyclophosphamide
DRUGcytarabine
DRUGdexamethasone
DRUGdoxorubicin hydrochloride
DRUGmethotrexate
DRUGvincristine sulfate
RADIATIONlow-LET cobalt-60 gamma ray therapy
RADIATIONlow-LET photon therapy

Timeline

Start date
1995-07-01
Primary completion
2006-10-01
Completion
2006-10-01
First posted
2004-06-10
Last updated
2016-07-14

Locations

21 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00002676. Inclusion in this directory is not an endorsement.